ArticleCancers2023

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR- or Very Elderly Post-Menopausal ER+/HER2- Advanced Breast Cancers.

Hiu Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.